+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Hand, Foot, and Mouth Disease

Catalog No Product Description CAS No. Purity Structural Formula
BP0684
Gomisin G
Gomisin G is a drug candidate for treatment of cardiovascular disease, and it is a good substrate of CYP2C9, and can be easily affected by the inhibitors of CYP2C9. Gomisin G exhibits anti-tumor activities, it exhibits potent anti-HIV activity with EC50 and therapeutic index (TI) values of 0.006 microgram/mL and 300, respectively.
62956-48-3 98% Gomisin G
BP1467
Ziyuglycoside I
Ziyuglycoside I has anti-wrinkle activity, could be used as an active ingredient for cosmetics.
35286-58-9 98% Ziyuglycoside I
BP4068
Dehydroandrographolide succinate
Dehydroandrographolide succinate can alleviate oxidative stress in LPS-induced acute lung injury possibly by inactivating iNOS. It combined with ribavirin treatedchildren with hand-foodand mouth disease,the duration of fever was shorter,rashes on hands and feet more quickyly.
786593-06-4 98% Dehydroandrographolide succinate
BPF2218
Norwogonin
Norwogonin is a trihydroxyflavone with the hydroxy groups at positions C-5, -7 and -8. It has a role as an antioxidant and a metabolite. Norwogonin(IC 50 = 1.1 microM) shows potent inhibitory activity toward VHR.
4443-09-8 98% Norwogonin
BP0417 1398-78-3 Cucurbitacin E-2-O-Glucoside
SBP03550 78536-37-5 Excisanin A
BP1066
Parthenolide
Parthenolide exhibits anti-cancer, anti-inflammatory, immunomodulatory, anti-Leishmania, and antimigraine effects, it inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.Parthenolide is also an inhibitor of the nuclear factor-kappaB pathway, can ameliorate cardiovascular derangement and outcome in endotoxic shock in rodents. (1Ar,7aS,10aS,10bS)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one is a germacranolide.
20554-84-1 98% Parthenolide
BP0482 4099-30-3 98% De-O-acetylcinobufotalin
BP2228 206876-12-2 98% Gylongiposide I
BP0786
Isoliensinine
Isoliensinine has anti-cancer, anti-fibrosis, anti-proliferative, antioxidant, and anti-inflammatory activities, it inhibited TNF-alpha and TGF-beta 1; decreased the overexpression of growth factors Platelet-derived growth factor (PDGF)-beta, basic fibroblast growth factor (bFGF), proto-oncogene c-fos, c-myc and hsp70; and activated ROS and p38 MAPK/JNK .
6817-41-0 98% Isoliensinine
BP2421 343569-15-3 98% Delicaflavone
BP0556
Escin IA
Escin IA is a prodrug and its structure can be converted to desacylescin I by human intestinal bacteria and Lactobacillus brevis., desacylescin I as a biotransformation product shows potentially inhibitory effects on mouse tumor, and a potential candidate for anti tumor agents. Escin IA has anti-TNBC metastasis activity, and its action mechanisms involved inhibition of EMT process by down-regulating LOXL2 expression.
123748-68-5 98% Escin IA
BP0086
Mosloflavone
Mosloflavone is an ether and a member of flavonoids. Mosloflavone is an antifungal and radical scavenging 2-hydroxyflavanone, it possesses strong anti-EV71 activity and decreased the formation of visible cytopathic effects, it also inhibits virus replication during the initial stage of virus infection, and inhibits viral VP2 protein expression, thereby inhibiting viral capsid protein synthesis. Mosloflavone shows promising anti-inflammatory activity via inhibition of TNF-α and IL-1β with IC50 values of 16.4 uM and 6.4 uM, respectively; it shows dose-dependent inhibition of TNF-α, IL-1β and iNOS levels in the supernatant of mouse macrophage cell line J774A, it also can be used as a starting point to discover lead structures for treatment of inflammatory and immunomodulatory diseases. Mosloflavone extracted from Scutellaria baicalensis Georgi has anti EV71 activity. Mosloflavone inhibits VP2 virus replication and protein expression during the initial stage of viral infection, as well as suppresses virus VP2 capsid protein synthesis. Mosloflavone is a promising fungicide that can inhibit the virulence and biofilm formation of Pseudomonas aeruginosa
740-33-0 98% Mosloflavone